Listed pharmas taking steps back in R&D investment

Published: 2017-11-17 13:25:03

Updated: 2017-11-17 13:25:03

Listed pharmaceutical companies were criticized that they took a step back in R&D investment.

Yakup Shinmoon(www.yakup.com) analyzed KOSPI and KOSDAQ listed pharmaceutical companies’ 2017 3^rd quarter business performances, and the analysis showed their average R&D expenses/sales ratio was 7.7%. <holding and biotech companies excluded from the analysis>

The ratio was decreased from 8.0% in 201...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.